Novel Treatment Approaches for Substance Use Disorders : Therapeutic Use of Psychedelics and the Role of Psychotherapy Michael Koslowski, Matthew W. Johnson, Gerhard Gründer, Felix Betzler Current Addiction Reports, 2021, 1-11. doi : 10.1007/s40429-021-00401-8 Abstract Purpose of Review : The use of psychedelics in a therapeutical setting has been reported for the treatment of various diagnoses in recent years. However, as psychedelic substances are still commonly known for their (illicit) recreational use, it may seem counterintuitive to use psychedelic therapy to treat substance use disorders. This review aims to discuss how psychedelics can promote and intensify psychotherapeutic key processes, in different approaches like psychodynamic and [...]
Lire la suiteMolecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans Paul Cumming, Milan Scheidegger, Dario Dornbierer, Mikael Palner, Boris B. Quednow and Chantal Martin-Soelch Molecules, 2021, 26, 2451 doi : 10.3390/molecules26092451 Abstract : Hallucinogens are a loosely defined group of compounds including LSD, N,Ndimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and ex vivo, and the various molecular imaging studies with positron [...]
Lire la suiteCannabidiol EPIDYOLEX 100 mg/ml, solution buvable Première évaluation COMMISSION DE LA TRANSPARENCE AVIS 13 MAI 2020 Haute Autorité de Santé, HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique Avis définitif L’essentiel Avis favorable au remboursement en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut (SLG) ou au syndrome de Dravet (SD), chez les patients de 2 ans et plus. Quel progrès ? Un progrès thérapeutique dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les patients de 2 ans et plus. Quelle place dans la stratégie thérapeutique ? Crises d’épilepsie [...]
Lire la suitePharmacologie du Cannabidiol : Points de vigilance, conséquences et risques chez l’homme Note rédigée par l’Association Française des centres d’Addictovigilance : Pr Joëlle MICALLEF, Dr Anne BATISSE, Dr Bruno REVOL, décembre 2021 Contexte Le Cannabidiol (CBD) est l’un des principaux phytocannabinoïdes présent dans Cannabis sativa, avec le THC. A ce jour, un seul produit contenant uniquement du CBD (nom de ce médicament Epidyolex®) est disponible sur le marché français, son Autorisation de Mise sur le Marché (AMM) lui conférant une indication médicale en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les [...]
Lire la suiteCANNABIDIOL (CBD) : Critical Review Report, WHO, 2018 Expert Committee on Drug Dependence Fortieth Meeting Geneva, 4-7 June 2018 Contents Acknowledgements .................................................................................................................. 4 Summary................................................................................................................................... 5 1. Substance identification ........................................................................................................ 6 A. International Nonproprietary Name (INN) ............................................................................ 6 B. Chemical Abstract Service (CAS) Registry Number .............................................................. 6 C. Other Chemical Names .......................................................................................................... 6 D. Trade Names .......................................................................................................................... 6 E. Street Names........................................................................................................................... 6 F. Physical Appearance.............................................................................................................. 6 G. WHO Review History ............................................................................................................. 6 2. Chemistry ............................................................................................................................... 6 A. Chemical Name ...................................................................................................................... 6 B. Chemical Structure................................................................................................................. 7 C. Stereoisomers ......................................................................................................................... 7 D. Methods and Ease of Illicit Manufacturing............................................................................ 7 E. Chemical Properties............................................................................................................... 9 F. Identification and Analysis ..................................................................................................... 9 3. Ease of Convertibility Into Controlled Substances ............................................................ 10 4. General Pharmacology........................................................................................................ 11 A. Routes of administration and [...]
Lire la suiteL’évaluation et l’efficacité des psychothérapies psychanalytiques et de la psychanalyse The evaluation and the efficacy of psychoanalytical therapies and psychoanalysis Thomas Rabeyron L’Évolution Psychiatrique, 2021, 86, 3, 455-488 Doi : 10.1016/j.evopsy.2020.07.003 Résumé Objectif. – Cet article propose une revue de littérature concernant l’évaluation et l’efficacité des psychothérapies psychanalytiques et de la psychanalyse (PPP). Méthode. – Après avoir proposé une vue d’ensemble de l’évaluation des psychothérapies, nous reprenons les travaux portant sur l’évaluation empirique et quantitative des PPP avant de nous centrer sur leur évaluation qualitative et processuelle.Résultats. – Les résultats des études menées en ce domaine démontrent que les psychothérapies sont efficaces aussi bien sur le court [...]
Lire la suiteLe Petit Livre du Cannabis Médical Nicolas Authier, Editions First, 2021, 149 pages Sommaire Petit livre Cannabis Médical - N Authier
Lire la suiteCannabinoid-based Medications for Pain Raymond M. St. Marie, MD; Raphael J. Leo, MA, MD Current Psychiatry, 2021, 20(5), 21-33. Abstract and Introduction Introduction Against the backdrop of an increasing opioid use epidemic and a marked acceleration of prescription opioid–related deaths,[1,2] there has been an impetus to explore the usefulness of alternative and co-analgesic agents to assist patients with chronic pain. Preclinical studies employing animal-based models of human pain syndromes have demonstrated that cannabis and chemicals derived from cannabis extracts may mitigate several pain conditions.[3] Because there are significant comorbidities between psychiatric disorders and chronic pain, psychiatrists are likely to care for patients with chronic pain. As [...]
Lire la suiteCannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis Mohamed M. Radwan, Suman Chandra, Shahbaz Gul and Mahmoud A. ElSohly Molecules, 2021, 26, 2774. Doi : 10.3390/molecules26092774 Abstract : Cannabis sativa is one of the oldest medicinal plants in the world. It was introduced into western medicine during the early 19th century. It contains a complex mixture of secondary metabolites, including cannabinoids and non-cannabinoid-type constituents. More than 500 compounds have been reported from C. sativa, of which 125 cannabinoids have been isolated and/or identified as cannabinoids. Cannabinoids are C21 terpeno phenolic compounds specific to Cannabis. The non-cannabinoid constituents include: non-cannabinoid phenols, flavonoids, terpenes, alkaloids and others. This review discusses [...]
Lire la suiteCannabis and cannabinoid use in autism spectrum disorder : a systematic review Estácio Amaro da Silva Junior, Wandersonia Moreira Brito Medeiros, Nelson Torro, João Marçal Medeiros de Sousa, Igor Bronzeado Cahino Moura de Almeida, Filipe Barbosa da Costa, Katiúscia Moreira Pontes, Eliane Lima Guerra Nunes, Marine Diniz da Rosa, Katy Lísias Gondim Dias de Albuquerque Trends in Psychiatry and Psychotherapy, 2021, 1-10. Doi : 10.47626/2237-6089-2020-0149 Abstract Introduction : Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction, associated with the presence of restricted and repetitive patterns of behavior, interests, or activities. Cannabis has been used to alleviate [...]
Lire la suite